RecruitingNot ApplicableNCT06627075

Optical Surface Guidance for External Radiotherapy of Head and Neck Cancer

Feasibility of Surface Optical Guidance to Replace the Restraint Mask for External Radiotherapy of Head and Neck Cancer

Sponsor

Center Eugene Marquis

Enrollment

40 participants

Start Date

Dec 12, 2024

Study Type

INTERVENTIONAL

Conditions

Otorhinolaryngeal Cancer

Summary

The goal of this clinical trial is to test the use of surface repositioning alone, without a restraint mask, during radiotherapy sessions for patients with head and neck cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Patients over 18 years of age
Patients undergoing palliative or curative treatment for oro-rhino-laryngeal cancer
Patients with an indication for radiotherapy treatment, with or without complementary treatment (chemotherapy, immunotherapy), with a number of sessions between 10 and 35
Patients who have dated and signed an informed consent form

Exclusion Criteria7

Patients with uncontrollable movements
Patients under psychiatric care
Patients who do not understand or read French
Patients participating in an interventional study testing another medical intervention
Patients under guardianship, curatorship, safeguard of justice or deprived of liberty
Pregnant or breast-feeding women
Patients without social security coverage

Interventions

PROCEDURESurface Guided RadioTherapy (SGRT) without mask

Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan. During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system. Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm). If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research. Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist.

Locations(1)

Centre de Lutte contre le Cancer Eugène Marquis

Rennes, Brittany Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06627075